

IAP12 Rec'd PCT/PTO 23 AUG 2006

Docket No.: 68970-235077
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
Francisco Javier Vila Pahi et al.

Art Unit: Not Yet Assigned

Application No: Not Yet Assigned

Examiner: Not Yet Assigned

Confirmation No: Not Yet Assigned

Filed: Concurrently Herewith

Atty. Docket No: 68970-235077

For: NEW THERAPEUTIC USE FOR A
GROUP OF SULPHATED
POLYSACCHARIDES

Customer No:

26694**26694**

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

References BA to BE and CA to CB are cited in an International Search Report issued in a corresponding PCT application. A concise explanation of these references is in the form of the

Application No.: Not Yet Assigned

Docket No.: 68970-235077

enclosed English language copy of the International Search Report, which refers to the relevant portions of the references.

Copies of the references are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 68970-235077. A Fee Transmittal is enclosed.

Dated: *August 23, 2006*

Respectfully submitted,

By 
Michael A. Sartori, Ph.D.

Registration No.: 41,289
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

#778495

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Francisco J. Vila Pahi	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	68970-235077

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-4,021,545	05-03-1977	Nair et al.	
	AB*	US-2003/0181416-A1	09-25-2003	Comper	
	AC*	US-4,699,900	10-13-1987	Bayol et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-03/006645 A	01-23-2003	Imclone Systems Incorporated		
	BB	EP-0 561 379 A	09-22-1993	Asahi Medical Co., Ltd.		
	BC	WO-92/13541 A	08-20-1992	Hoechst Aktiengesellschaft		√
	BD	WO-02/36132 A	05-10-2002	Laboratoires Goemar S.A.		
	BE	WO-2005/054446 A	06-16-2005	Universiteit Gent		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Database CA Online!: Accession No. 1999-492587; Minami, S. et al., "Veterinary-clinical uses of curdlan sulfate," XP002347885, Chemical Abstracts Service, Columbus, Ohio (1999).	
	CB	Miyamoto, K. et al., "Novel plasma-separation dilayer gellan-gellan-sulfate adsorber for direct removal of extra domain A containing fibronectin from the blood of rheumatoid arthritis patients," International Journal of Biological Macromolecules, Vol. 30, No. 3-4, pages 197-204 (2002).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

#778497

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--